Diversity in antibody-based approaches to non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 51, Issue SUPPL. 1, 2010, Pages 20-27

  Maloney, David ^a   Morschhauser, Franck ^b   Linden, Ola ^c   Hagenbeek, Anton ^d   Gisselbrecht, Christian ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

antibodies; B cells; CD20; monoclonal; Non Hodgkin lymphoma

Indexed keywords

AME 133; ANTIHISTAMINIC AGENT; CARMUSTINE; CD19 ANTIGEN; CD20 ANTIBODY; CD22 ANTIGEN; CD52 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GA 101; IBRITUMOMAB TIUXETAN; MELPHALAN; OCRELIZUMAB; OFATUMUMAB; PREDNISOLONE; PREDNISONE; PRO 131921; RITUXIMAB; STEROID; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE SULFATE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BINDING AFFINITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEVER; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDOLENT LYMPHOMA; LARGE CELL LYMPHOMA; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SURVIVAL RATE; TOXICITY; TREATMENT RESPONSE; UNITED STATES; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 77956445009     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.500047     Document Type: Review

References (64)

1. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society, 2010. Available online 5http://www.cancer.org/acs/ groups/content/@nho/documents/document/acspc-024113.pdf4. Last accessed July 28, 2010.
2. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469-476.
3. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256: 495-497.
4. Winter G, HarrisWJ. Humanized antibodies. Immunol Today 1993;14:243-246. (Pubitemid 23186983)
5. Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005;98:146-152.
6. Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkins lymphoma. Neth J Med 2009;67:311-321.
7. Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematol Am Soc Hematol Educ Program 2007;226-232.
8. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000;27:17-24.
9. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003;278:42427-42434.
10. OKeefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48: 125-132.
11. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-371.
12. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22: 7359-7368.
13. Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkins lymphoma. Biologics 2008;2:619-633.
14. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101: 2507-2513.
15. van Oers MH.Monoclonal antibodies in the treatment of non-Hodgkins lymphoma: moving targets. Neth J Med 2009;67: 309-310.
16. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advancedstage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732.
17. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plusrituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.
18. Herold M, Haas A, Srock S, et al. Rituximab added to firstline mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-1992.
19. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-4831.
20. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
21. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466.
22. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
23. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkins lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-4716.
24. Forstpointner R, DreylingM, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071.
25. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-Bcell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
26. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkins lymphoma. Semin Oncol 2002;29:18-22. (Pubitemid 34594980)
27. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkins lymphoma. Leuk Lymphoma 2005;46:1569-1573.
28. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.NEngl JMed 2002;346:235-242.
29. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkins lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-3143.
30. Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005;28:212-219.
31. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181:822-832.
32. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749-758.
33. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase trial. Blood 2008;111:5486-5495.
34. Wierda W, Kipps T, Mayer J, et al. High activity of single-agent ofatumumab, a novel CD20 monoclonal antibody, in fludarabine- and alemtuzumab-refractory or bulky fludarabine- refractory chronic lymphocytic leukemia, regardless of prior rituximab exposure. 14th Congress of the European Hematology Association, 2009.
35. Milani C, Castillo J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther 2009;11:200-207.
36. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkins lymphoma: phase I/II results. J Clin Oncol 2009;27:3346-3353.
37. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010;21:1870-1876
38. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-2654.
39. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkins lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-5334.
40. Cesano A, Gayko U, Brannan C. Differential expression of CD22 by indolent and aggressive NHLs: implications for targeted immunotherapy. Blood 2002;100:(Abstract 350).
41. Sato S, Miller AS, Inaoki M, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996;5:551-562.
42. Otipoby KL, Andersson KB, Draves KE, et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 1996;384:634-637.
43. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, aCD22-targeting recombinant humanized antibodywith a differentmode of action from rituximab. Mol Immunol 2007;44:1331-1341.
44. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkins lymphoma. J Clin Oncol 2003;21:3051-3059.
45. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008;14:6154-6160.
46. Morschhauser F, Kraeber-Bodéré F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkins lymphoma. J Clin Oncol. Published ahead of print on July 26, 2010 as 10.1200/JCO.2009. 27.7863.
47. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714-2723.
48. Micallef I, Maurer M, Nikcevich D. Final results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2009;27: (Abstract 8508).
49. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008;112:830-835.
50. Illidge TM, Bayne M, Brown NS, et al. Phase study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113:1412-1421.
51. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786-792.
52. Hess G. Radioimmunotherapy- still experimental? Rational, proven indications and future trends. Memo 2008;1:193-203.
53. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkins lymphoma: in pursuit of a complete response. Oncologist 2009;14 (Suppl 2): 41-51.
54. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104:2667-2674.
55. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005;105:3817-3823.
56. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by highdose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe dEtude des Lymphomes de lAdulte (GELA). Blood 2006;108:2540-2544.
57. Morschhauser F, Radford J, Van HA, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
58. Morschhauser F, Bishof-Delaloye A, Rohatiner AZS, et al. Extended follow-up of the international randomized phase 3 first-line indolent trial (FIT) shows durable benefit of 90YIbritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage folicular non-Hodgkins lymphoma. 50th ASH Annual Meeting 2008.
59. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkins lymphoma. N Engl J Med 1995;333:1540-1545.
60. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934-2942.
61. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkins lymphoma. J Clin Oncol 2008;26:90-95.
62. Gisselbrecht C, Decaudin D, Mounier N, et al. 90 Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (ZBEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. A GELA Phase II prospective study. Haematologica 2009;94(Suppl. 2):418 (Abstract 1042).
63. Nademanee A, Forman S, Molina A, et al. A phase trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896-2902.
64. Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkins lymphoma. J Clin Oncol 2009;27: 1653-1659.